Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Nanobiotix    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
7.18(c) 7.08(c) 6.89(c) 6.96(c) 6.93 Last
30 958 48 145 82 016 34 697 18 431 Volume
-1.78% -1.39% -2.68% +1.02% -0.43% Change
More quotes
Financials
Sales 2020 4,00 M 4,53 M 4,53 M
Net income 2020 -46,1 M -52,2 M -52,2 M
Net Debt 2020 57,2 M 64,7 M 64,7 M
P/E ratio 2020 -3,36x
Yield 2020 -
Sales 2021 10,6 M 12,0 M 12,0 M
Net income 2021 -45,9 M -52,0 M -52,0 M
Net Debt 2021 122 M 139 M 139 M
P/E ratio 2021 -3,66x
Yield 2021 -
Capitalization 158 M 179 M 179 M
EV / Sales 2020 53,8x
EV / Sales 2021 26,5x
Nbr of Employees 110
Free-Float 98,1%
More Financials
Company
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the local treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without... 
More about the company
Surperformance© ratings of Nanobiotix
Trading Rating : Investor Rating : -
More Ratings
Latest news on NANOBIOTIX
06/17NANOBIOTIX : Receives Feedback From US FDA to Advance Phase III Head and Neck Ca..
BU
06/10CURADIGM : Announces Publication of Results Using Proprietary Nanoprimer to Impr..
BU
06/10NANOBIOTIX : Spinoff Curadigm Validates Novel Nanoprimer Technology in RNA Thera..
BU
06/09NANOBIOTIX : Secures EUR10M in Non-Dilutive Financing
AQ
06/08NANOBIOTIX : Secures €10M in Non-Dilutive Financing
BU
05/29NANOBIOTIX : Announces Positive First Results From Phase I Expansion in Locally ..
BU
05/14NANOBIOTIX : Publication of the 2019 Universal Registration Document
BU
05/06NANOBIOTIX : Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is S..
BU
04/30NANOBIOTIX : Announces First Quarter 2020 Revenues
BU
04/30NANOBIOTIX : 1st quarter earnings
CO
04/21NANOBIOTIX : Provides Updates on Clinical Development Continuity in the Context ..
BU
03/17NANOBIOTIX : 2019 Annual Results
BU
03/17NANOBIOTIX : Annual results
CO
03/09CURADIGM : announces the selection of its Nanoprimer technology by the National ..
BU
02/28NANOBIOTIX : 2019 Q4 and Annual Revenues
BU
More news
News in other languages on NANOBIOTIX
07/02NANOBIOTIX : 2020 : bilan semestriel du contrat de liquidité contracté avec la s..
06/18Stop ou encore ?
06/18EN DIRECT DES MARCHES : PSA, FDJ, Airbus, Elis, Valneva, Nokia, Swatch, TUI, Nis..
06/17NANOBIOTIX : Receives Feedback From US FDA to Advance Phase III Head and Neck Ca..
06/17NANOBIOTIX : Recoit les commentaires de la fda pour avancer son etude de phase i..
More news
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 22,63 €
Last Close Price 6,96 €
Spread / Highest target 503%
Spread / Average Target 225%
Spread / Lowest Target 50,9%
EPS Revisions
Managers
NameTitle
Laurent Lévy Chief Executive Officer
Laurent Condomine Chairman-Supervisory Board
Alain Dostie Chief Operating Officer
Philippe Mauberna Chief Financial Officer
Margaret Galluzzi Vice President-Global & Head-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
NANOBIOTIX-15.94%179
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344